NANJING HICIN PHARMACEUTIC

Chinese Pharma Stock Review: Nanjing Hicin Holds Steady, Zq Surges With New Credit

Explore Nanjing Hicin Pharmaceutic’s flat yet bullish 2026 trading snapshot, market cap insights, and peer comparison—ideal for investors eyeing stable pharma growth.

NANJING HICIN PHARMACEUTIC
China
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Jake Connors

26/10/2026, 09:45

3 minutes to read

Hold Steady: Nanjing Hicin Pharmaceutic’s Flat 0% Movement Signals Stable Outlook Amid Volatility

Explore Nanjing Hicin Pharmaceutic’s steady stock performance, 0% change and 3.3 bn CNY market cap, and potential rebound amid sector volatility.

NANJING HICIN PHARMACEUTIC
China
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Samantha Roth

24/10/2026, 01:15

3 minutes to read